ProAgio and gemcitabine for triple-negative breast cancer that has spread
Part of Cancer, Skin clinical trials.
This trial tests a new drug called ProAgio combined with the chemotherapy gemcitabine for people with triple-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your breast cancer must be triple-negative (ER, PR, and HER2 negative) and has spread to other organs.
- You must have already tried at least two different treatments for advanced cancer.
- You must be willing to provide a tumor sample and have a research biopsy before and during treatment.
- You need to be in generally good health with adequate blood cell counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
This trial tests a new immunotherapy drug (cadonilimab) combined with a chemotherapy (eribulin) against chemotherapy alone for triple-negative breast cancer that has come back or spread. If you receive the combination, the goal is to see if it helps control the cancer better or for longer.
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
This trial tests a combination of an immunotherapy drug (PD-L1 antibody) along with a low-dose oral chemotherapy ('metronomic') called VEX for people with advanced triple-negative breast cancer. The goal is to see if this combination is safe and effective in controlling the cancer.
This trial compares two chemotherapy drugs to see which works better for Black women of Caribbean or Ghanaian ancestry with metastatic triple-negative breast cancer. It aims to find a more effective treatment for this group.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.